ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
ADC Therapeutics收到纽约证券交易所不遵守持续上市标准的通知
ADC Therapeutics SA (NYSE:ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.
ADC Therapeutics SA（纽约证券交易所代码：ADCT）今天宣布，它于2023年10月10日收到纽约证券交易所（NYSE）的通知，称该公司不符合《纽约证券交易所上市公司手册》第802.01C节规定的持续上市最低价格标准，该标准要求上市公司在连续30个交易日内将平均收盘价维持在至少1.00美元。